Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological equivalence of 0.002% DE-117B vs 0.002% Omidenepag Isopropyl in primary open-angle glaucoma or ocular hypertension
jRCT2080225126Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of omidenepag isopropyl in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Santen Pharmaceutical. Started Mar 2020; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080225126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225126.